The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.
Additionally, patients administered with PBF-680 showed statistically significant improvement compared to placebo treated patients in most of the secondary endpoints evaluated, including FEV1 AUC on day 15 and the Asthma Control Questionnaire.
Remarkably, PBF-680 treatment caused a robust decrease in eosinophil counts at day 15, which recover to normal values two weeks later.
No serious adverse events were reported in the trial, demonstrating once again the very good safety and tolerability profile of the compound.
El gen AtCDF3 promueve una mayor producción de az...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Palobiofarma S.L. se complace en anunciar la finalización del tratami...
Portal de biotecnología en España
¡Suscríbase a nuestro newsletter para estar al día con las últimas noticias y ofertas!
2013 © Biotech-Spain.com - Site Developments SL. Todos los derechos reservados. Terminos y Condiciones | Política de Privacidad
Articles
Directory